Adjuvant Capital

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations. 54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research is caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, more affordable, and more accessible globally. VitriVax is headquartered in Boulder, Colorado.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Frontier Nutrition develops, manufacture, and markets packaged food products. Their products and strategies are based on research in pediatric nutrition and behavioral marketing. Their recipes are localized for traditional diets and optimized for taste, nutrition, and price. Frontier Nutrition, Inc. was founded in 2017 by Eddie Bearnot and Tanveer Ali and is based in New Haven, Connecticut, United States.

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%. Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Evofem is a biopharmaceutical company that offers women's reproductive and contraceptive care products. The company's first commercial product, Phexxi, is the first and only hormone-free, prescription vaginal gel approved in the United States to prevent pregnancy.

ChromaCode is a molecular diagnostics company focusing on bioinformatics. It leverages patented mathematical methods and algorithmic enhancements to enrich signal processing from life science instrumentation. The company uses this to extract new information on biochemistry reactions and substantially increase the performance capabilities of today’s gold-standard biochemical assays at a very low cost. ChromaCode was founded in 2012, ChromaCode is headquartered in Carlsbad, California.

54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations. 54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research is caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.

AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

InDevR is a biotechnology company that develops and manufactures microarray technologies and applications as well as novel solutions to support the life sciences industry. It was incorporated in 2003 and is based in Boulder, Colorado.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.